Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs
- PMID: 19897178
- PMCID: PMC3677042
- DOI: 10.1016/j.biopsych.2009.08.040
Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs
Abstract
Background: A standardized quantitative method for comparing dosages of different drugs is a useful tool for designing clinical trials and for examining the effects of long-term medication side effects such as tardive dyskinesia. Such a method requires establishing dose equivalents. An expert consensus group has published charts of equivalent doses for various antipsychotic medications for first- and second-generation medications. These charts were used in this study.
Methods: Regression was used to compare each drug in the experts' charts to chlorpromazine and haloperidol and to create formulas for each relationship. The formulas were solved for chlorpromazine 100 mg and haloperidol 2 mg to derive new chlorpromazine and haloperidol equivalents. The formulas were incorporated into our definition of dose-years such that 100 mg/day of chlorpromazine equivalent or 2 mg/day of haloperidol equivalent taken for 1 year is equal to one dose-year.
Results: All comparisons to chlorpromazine and haloperidol were highly linear with R(2) values greater than .9. A power transformation further improved linearity.
Conclusions: By deriving a unique formula that converts doses to chlorpromazine or haloperidol equivalents, we can compare otherwise dissimilar drugs. These equivalents can be multiplied by the time an individual has been on a given dose to derive a cumulative value measured in dose-years in the form of (chlorpromazine equivalent in mg) x (time on dose measured in years). After each dose has been converted to dose-years, the results can be summed to provide a cumulative quantitative measure of lifetime exposure.
Copyright 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Competing Interests: Dr. Andreasen has received honoraria for a lecture from Eli Lilly and a lecture honorarium, an advisory board consulting fee, and research funding from Janssen-Cilag; Dr. Miller has received consulting fees from Organon Schering Plough and Otsuka Pharmaceuticals; Dr. Ho has received research funding from Janssen-Cilag. Drs. Nopoulos and Pressler reported no biomedical financial interests or potential conflicts of interest.
Figures
Similar articles
-
Chlorpromazine equivalent doses for the newer atypical antipsychotics.J Clin Psychiatry. 2003 Jun;64(6):663-7. doi: 10.4088/jcp.v64n0607. J Clin Psychiatry. 2003. PMID: 12823080 Review.
-
Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug doses?J Clin Psychopharmacol. 2003 Dec;23(6):657-9. doi: 10.1097/01.jcp.0000096247.29231.3a. J Clin Psychopharmacol. 2003. PMID: 14624195
-
Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.Turk Psikiyatri Derg. 2022 Summer;33(2):146-148. doi: 10.5080/u26315. Turk Psikiyatri Derg. 2022. PMID: 35730516 English, Turkish.
-
Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.Psychopharmacology (Berl). 2004 Oct;176(1):94-100. doi: 10.1007/s00213-004-1866-y. Epub 2004 Apr 9. Psychopharmacology (Berl). 2004. PMID: 15083255
-
Plasma level monitoring of antipsychotic drugs. Clinical utility.Clin Pharmacokinet. 1986 Jan-Feb;11(1):36-61. doi: 10.2165/00003088-198611010-00003. Clin Pharmacokinet. 1986. PMID: 2868820 Review.
Cited by
-
Working memory in schizophrenia: The role of the locus coeruleus and its relation to functional brain networks.Brain Behav. 2021 May;11(5):e02130. doi: 10.1002/brb3.2130. Epub 2021 Mar 30. Brain Behav. 2021. PMID: 33784023 Free PMC article.
-
Molecular signatures associated with cognitive deficits in schizophrenia: a study of biopsied olfactory neural epithelium.Transl Psychiatry. 2016 Oct 11;6(10):e915. doi: 10.1038/tp.2016.154. Transl Psychiatry. 2016. PMID: 27727244 Free PMC article.
-
Altered threat and safety neural processing linked to persecutory delusions in schizophrenia: a two-task fMRI study.Psychiatry Res. 2015 Sep 30;233(3):352-66. doi: 10.1016/j.pscychresns.2015.06.002. Epub 2015 Jun 23. Psychiatry Res. 2015. PMID: 26208746 Free PMC article.
-
Multi-dimensional predictions of psychotic symptoms via machine learning.Hum Brain Mapp. 2020 Dec 15;41(18):5151-5163. doi: 10.1002/hbm.25181. Epub 2020 Sep 1. Hum Brain Mapp. 2020. PMID: 32870535 Free PMC article.
-
Differential Time Course of Microstructural White Matter in Patients With Psychotic Disorder and Individuals at Risk: A 3-Year Follow-up Study.Schizophr Bull. 2017 Jan;43(1):160-170. doi: 10.1093/schbul/sbw061. Epub 2016 May 17. Schizophr Bull. 2017. PMID: 27190279 Free PMC article.
References
-
- Andreasen NC, Flaum M, Arndt S. The comprehensive assessment of symptoms and history (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry. 1992;49:615–623. - PubMed
-
- Miller DD, Flaum M, Nopoulos P, Arndt S, Andreasen NC. The concept of dose years: A reliable method for calculating lifetime psychotropic drug exposure. Schizophr Res. 1995;15:159.
-
- Davis JM. Dose equivalence of the antipsychotic drugs. J Psychiatr Res. 1974;11:65–69. - PubMed
-
- Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64:663–667. - PubMed
-
- Kane JM, Leucht S, Carpenter D, Docherty JP. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: Methods, commentary, and summary. J Clin Psychiatry. 2003;64(suppl 12):5–19. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources